April 29, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post

April 24, 2025

Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer

Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lun...

The ASCO Post

April 24, 2025

Final Results of LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC

As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, and colleagues, final results of the reg...

The ASCO Post

April 21, 2025

Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?

In a recent article, the use of tyrosine kinase inhibitors in treating EGFR-variant lung adenocarcinoma is explored, drawing comparisons to their use in chronic myeloid leukemia, highlighting similarities and differences.

The ASCO Post

April 18, 2025

Activity of ROS1 TKI in NSCLC

A pooled analysis of the phase II TRUST-I and TRUST-II trials reported efficacy and safety findings on the use of the oral next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib in ROS1-po...

The ASCO Post

April 04, 2025

Smoking Status of the U.S. Cancer Population

In a study reported as a research letter in JAMA Oncology, Caturegli et al attempted to identify smoking status of patients diagnosed with cancer in the United States in 2023.

The ASCO Post

April 03, 2025

Patterns in Adherence to USPSTF Lung Cancer Screening Guidelines

In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelin...

The ASCO Post

April 03, 2025

AI Integration in Global Programs of CT Screening for Lung Cancer and Other Tobacco-Related Illnesses

A new consortium, the Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE) has proposed a public health program of longitudinal chest CT screenings amon...

The ASCO Post

March 06, 2025

Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?

Based on a systematic review and meta-analysis, plasma circulating tumor DNA (ctDNA) kinetics was found to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCL...

The ASCO Post